1. World Health Organization. HepatitisC.2010 http://www.who.int/csr/disease/hepatitis/ whocdscsrlyo2003/en/index.html. Arrival date, .
2. Mallet V, Vallet-Pichard A, Pol S. New trends in hepatitis C management. Presse Med. 2010; 39(4): 446-51.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74.
4. Ersöz G.Treatment of Hepatitis C. Turkiye Klinikleri J Gastroenterohepatol-Special Topics. 2010; 3(1): 96-102.
5. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010; 40(1): 8-13.
6. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007; (Suppl): 25-34.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 22; 358(9286):958-65.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr,et at. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82.
9. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P,et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55.
10. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010; 70(2): 147-65.
11. Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics. 2009; 3: 141-50.
12. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004; 350(22): 2265-71.
13. Garg G, Kar P. Management of HCV infection: current issues and future options. Trop Gastroenterol. 2009; 30(1): 11-8.
14. Mendoza J, Trapero-Marugán M, González-Moreno L, Jones EA, Gómez-Domínguez E, Moreno-Otero R. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy. Rev Esp Enferm Dig. 2010; 102(7): 426-34.
15. Shiffman ML. Treatment of hepatitis C in 2011: what can we expect? Curr Gastroenterol Rep. 2010; 12(1): 70-5.
16. Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res. 2010; 131: 17-34.
17. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J,et al. IDEAL Study Team.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6): 580-93.
18. Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST,et al. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology. 2010; 53(3): 146-53.
19. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138(1): 116-22.
20. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010; 51(4): 1176-84.
21. Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection. 2008; 36(4): 341-4.
22. Ceylan B, Fincancı M, Müderrisoğlu C, Eren G, Soysal F. Variables predicting virologic response to pegylated interferon and ribavirin treatment in patients with chronic hepatitis C. Turkish Journal of Infection. 2009; 23: 185-92.
23. Senturk H, Ersoz G, Ozaras R, Kaymakoglu S, Bozkaya H, Akdogan M. Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial. Dig Dis Sci. 2003; 48(6): 1124-9.
24. Yenice N, Mehtap O, Gümrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.Turk J Gastroenterol.2006; 17(2): 94-8.25.Xin Sun, Carrie D, Clara Williams, Caitlyn A. Senger, Tanya J. Kapka, Evelyn P. Whitlock, Interventions To Improve Patient Adherence toHepatitis C Treatment: Comparative Effectiveness ) Research Review – Final. 2012; 20.
26. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS,et al. Pegylated interferon-alpha plus ribavirin for treatment naive Asian patient with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. 2008; 47(10): 1260-9.
27. Jung YK, Kim JH, Ahn SM at al. Role of Interleukin 28B-related Gene Polymorphisms in Chronic Hepatitis C and the Response to Antiviral Therapy in Koreans. J Clin Gastroenterol. 2013; 24.
28. Aktaş E, Ogedey ED, Külah C, Beğendik Cömert F. [Hepatitis C virus genotypes in a province of western Black-Sea region, Turkey]. Mikrobiyol Bul. 2010; 44(4): 647-50.
29. Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis. 2008; 12(3): 239-44.